Onglyza and Type 2 diabetes - a phase IV clinical study of FDA data

Summary:

Type 2 diabetes is reported as a side effect among people who take Onglyza (saxagliptin hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 10+ years also take Cardizem, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Type 2 diabetes when taking Onglyza. It is created by eHealthMe based on reports of 8,520 people who have side effects when taking Onglyza from the FDA, and is updated regularly.

What is Onglyza?

Onglyza has active ingredients of saxagliptin hydrochloride. It is often used in diabetes. eHealthMe is studying from 8,638 Onglyza users. Check the latest studies of Onglyza.

What is Type 2 diabetes?

Type 2 diabetes is found to be associated with 1,431 drugs and 2,346 conditions by eHealthMe. Check the latest studies of Type 2 diabetes.

On Jul, 27, 2026

8,520 people reported to have side effects when taking Onglyza.
Among them, 42 people (0.49%) have Type 2 diabetes.

Among these 42 people:

How long have people been on Onglyza when they have Type 2 diabetes? *

What is the gender of people who have Type 2 diabetes when taking Onglyza? *

female: 69.05 %
male: 30.95 %

What is the age of people who have Type 2 diabetes when taking Onglyza? *

What are other drugs people take besides Onglyza? *

What are other side effects people have besides Type 2 diabetes? *

Weakness: 20 people, 47.62%
Weight Increased: 17 people, 40.48%
Dyspnea (difficult or laboured breathing): 15 people, 35.71%
Pneumonia: 15 people, 35.71%
Blood Glucose Increased: 15 people, 35.71%
Fatigue (feeling of tiredness): 15 people, 35.71%
Abdominal Pain: 14 people, 33.33%
Anaemia (lack of blood): 14 people, 33.33%
Thirst - Excessive: 14 people, 33.33%
Nosebleed (bleeding from nose): 14 people, 33.33%

What are the existing conditions these people have? *

High Blood Cholesterol: 10 people, 23.81%
Gastrointestinal Angiodysplasia (a small vascular malformation of the gut): 9 people, 21.43%
High Blood Pressure: 6 people, 14.29%
Blood Pressure Abnormal: 6 people, 14.29%
Gastrointestinal Angiodysplasia Haemorrhagic (a small vascular malformation of the gut with bleeding): 4 people, 9.52%
Stress And Anxiety: 3 people, 7.14%
Gastric Disorder (disease of stomach): 3 people, 7.14%
Insomnia (sleeplessness): 3 people, 7.14%
Migraine (headache): 2 people, 4.76%
Heart Attack: 2 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Onglyza and have Type 2 diabetes?

- Check whether Type 2 diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Onglyza:

Onglyza (8,638 reports)

Type 2 diabetes treatments and more:

Type 2 diabetes (391,582 reports)

Browse all side effects of Onglyza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type 2 diabetes:

Type 2 diabetes (1,431 drugs)

Browse all the conditions that are associated with Type 2 diabetes:

Type 2 diabetes (2,346 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on saxagliptin hydrochloride (the active ingredients of Onglyza) and Onglyza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.